Clinical Conditions "Suggestive of Progressive Supranuclear Palsy"-Diagnostic Performance.
autopsy
clinical diagnostic criteria
early diagnosis
neuropathology
progressive supranuclear palsy
suggestive
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
05
2020
revised:
04
08
2020
accepted:
10
08
2020
pubmed:
12
9
2020
medline:
28
4
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level "suggestive of progressive supranuclear palsy" for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves. To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort. Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other neurological diseases. The conditions suggestive of progressive supranuclear palsy strongly increased the sensitivity compared to the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy criteria. Within the first year after symptom onset, 40% of patients with definite progressive supranuclear palsy fulfilled criteria for suggestive of progressive supranuclear palsy. Two-thirds of patients suggestive of progressive supranuclear palsy evolved into probable progressive supranuclear palsy after an average of 3.6 years. Application of the criteria for suggestive of progressive supranuclear palsy reduced the average time to diagnosis from 3.8 to 2.2 years. Clinical conditions suggestive of progressive supranuclear palsy allow earlier identification of patients likely to evolve into clinically possible or probable progressive supranuclear and to have underlying progressive supranuclear palsy pathology. Further work needs to establish the specificity and positive predictive value of this category in real-life clinical settings, and to develop specific biomarkers that enhance their diagnostic accuracy in early disease stages. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
The Movement Disorder Society diagnostic criteria for progressive supranuclear palsy introduced the diagnostic certainty level "suggestive of progressive supranuclear palsy" for clinical conditions with subtle signs, suggestive of the disease. This category aims at the early identification of patients, in whom the diagnosis may be confirmed as the disease evolves.
OBJECTIVE
To assess the diagnostic performance of the defined clinical conditions suggestive of progressive supranuclear palsy in an autopsy-confirmed cohort.
METHODS
Diagnostic performance of the criteria was analyzed based on retrospective clinical data of 204 autopsy-confirmed patients with progressive supranuclear palsy and 216 patients with other neurological diseases.
RESULTS
The conditions suggestive of progressive supranuclear palsy strongly increased the sensitivity compared to the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy criteria. Within the first year after symptom onset, 40% of patients with definite progressive supranuclear palsy fulfilled criteria for suggestive of progressive supranuclear palsy. Two-thirds of patients suggestive of progressive supranuclear palsy evolved into probable progressive supranuclear palsy after an average of 3.6 years. Application of the criteria for suggestive of progressive supranuclear palsy reduced the average time to diagnosis from 3.8 to 2.2 years.
CONCLUSIONS
Clinical conditions suggestive of progressive supranuclear palsy allow earlier identification of patients likely to evolve into clinically possible or probable progressive supranuclear and to have underlying progressive supranuclear palsy pathology. Further work needs to establish the specificity and positive predictive value of this category in real-life clinical settings, and to develop specific biomarkers that enhance their diagnostic accuracy in early disease stages. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 32914550
doi: 10.1002/mds.28263
pmc: PMC7953080
mid: NIHMS1677370
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2301-2313Subventions
Organisme : NIA NIH HHS
ID : L30 AG064696
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG059891
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG066597
Pays : United States
Organisme : Medical Research Council
ID : MR/L016397/1
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R01 NS109260
Pays : United States
Informations de copyright
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Semin Neurol. 2014 Apr;34(2):160-73
pubmed: 24963675
Neurology. 1994 Nov;44(11):2015-9
pubmed: 7969952
Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23
pubmed: 25495175
Curr Opin Neurol. 2010 Aug;23(4):394-400
pubmed: 20610990
Prog Neurobiol. 2019 Sep;180:101644
pubmed: 31238088
J Neurol. 1999 Sep;246 Suppl 2:II6-15
pubmed: 10525997
Mov Disord. 2017 Jul;32(7):995-1005
pubmed: 28500752
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566
Lancet Neurol. 2009 Dec;8(12):1150-7
pubmed: 19909913
Neuropathol Appl Neurobiol. 2007 Dec;33(6):615-20
pubmed: 17990994
Mov Disord. 2020 Jan;35(1):171-176
pubmed: 31571273
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
Mov Disord. 2019 Aug;34(8):1228-1232
pubmed: 30884545
J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105
pubmed: 8558176